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Background/aim: T-helper cell type 1 (Th1)/Th2 cytokine balance is involved in the resistance or susceptibility to Brucella infection.
The analysis of cytokine levels is valuable to determine the role of the immune system in Brucella prognosis. The aim of this study was to
investigate the levels of serum interleukin-17 (IL-17) and transforming growth factor beta (TGF-β) and their alterations with treatment
in patients with acute brucellosis.
Materials and methods: TGF-β was tested in 33 acute brucellosis patients and 19 controls and IL-17 was analyzed in 40 patients and 12
controls. Cytokine levels were tested in controls and patients before and after treatment by ELISA.
Results: TGF-β levels were significantly lower in brucellosis cases compared to controls. At the end of the treatment, the serum levels
of this cytokine had increased, but there was no significant difference between this cytokine level before and after treatment. The IL-17
level was significantly higher in the brucellosis group compared to controls and its value decreased in patients at the end of treatment
without any significant difference.
Conclusion: This study indicated that TGF-β was lower and IL-17 was higher in brucellosis cases and, after treatment, the serum level
of TGF-β increased and that of IL-17 decreased in these patients.
Key words: Brucellosis, transforming growth factor beta, TGF-β, interleukin-17, IL-17

1. Introduction
Brucella species are gram-negative, nonmotile,
nonencapsulated, and facultative intracellular bacteria
that can cause chronic zoonotic disease in humans (1,2).
Domestic and wild animals are reservoirs of the bacteria,
which are usually transmitted to humans through the
consumption of contaminated unpasteurized dairy
products, direct contact with infected animals, and
inhalation of infected aerosols (3). Brucellosis is the most
common bacterial zoonotic disease worldwide, over half
a million people being infected annually, and it causes
serious health problems and economic losses (4,5).
Despite control of this organism in many countries,
it remains endemic in the Mediterranean and Middle
Eastern regions, including Iran (2,6,7). The prevalence of
brucellosis in Iran has been reported from 0.5% to 10.9% in
* Correspondence: araghakhani@hotmail.com
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different provinces. It has been reported that the majority
of isolates were identified as Brucella melitensis and it is
highly endemic in certain parts of Iran, such as Markazi
Province, with a 5-year incidence of about 40/100,000
(8,9).
Brucella spp. survive within a variety of cells, including
macrophages, and spread in mononuclear phagocytes to
reticuloendothelial sites (10,11). Both cell-mediated and
humoral immunity are responsible for the clearance of
Brucella infection (11,12). Host protection against Brucella
spp. primarily depends on cell-mediated immunity,
involving mainly activated antigen-presenting cells
(macrophages, dendritic cells) and CD4+ and CD8+
T-lymphocytes (2,10).
Cytokine profiles can be considered as T-helper cell
type 1 (Th1), Th2, or Th3 responses. The Th1/Th2 balance
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may be involved in the susceptibility or resistance to
brucellosis (1). Promoting Th1 cell-mediated immune
response causes clearance of Brucella and is under the
control of major cytokines like interferon gamma (IFN-γ),
tumor necrosis factor alpha (TNF-α), and interleukin-12
(IL-12), which are produced at the onset of infection.
However, activation of Th2 responses promotes humoral
immunity (IL-4, IL-5, IL-9, IL-13, IL-10), suppresses the
macrophage function, and increases the susceptibility to
infection (13–16).
The Th3 subset induces transforming growth factor
beta (TGF-β), a multifunctional cytokine that regulates
several pathways in the growth and differentiation of many
cell types (1). It is an antiinflammatory cytokine secreted
by activated T cells and macrophages, and it promotes the
humoral response (17). This cytokine suppresses cellular
immunity at multiple levels and inhibits lymphocyte
proliferation and function (18).
The IL-17 family is a group of newly described
cytokines. The IL-17 cytokine family consists of six
members (IL-17A to IL-17F) and five receptors (IL-17RA
to IL-17RD and SEF) (10). IL-17A (hereafter referred to
as IL-17)-producing T cells are distinct from the classic
Th1 and Th2 cells (19,20). IL-17 induces IL-12 and IFN-γ
production in macrophages and mediates bacterial
killing. It also regulates IL-12/Th1 immunity and the host
responses to intracellular pathogens. It thus seems that
IL-17 may have a main role in protection against Brucella
infection (10).
Previously, some cytokines such as IFN-γ, IL-2, IL3, IL-4, IL-12, and IL-6 have been studied in human
brucellosis (21–24). However, the precise role of other
cytokines in brucellosis has not been studied. Newly
described cytokines such as IL-17 and TGF-β introduce
new aspects of the immune response that might clarify
the unsolved problems in the immunology of brucellosis.
The aim of this study was to investigate the levels of serum
IL-17 and TGF-β and their alterations with treatment in
patients with acute brucellosis.
2. Material and methods
This study was carried out with patients with acute
brucellosis and aged-matched controls living in Markazi
Province of Iran (Arak city) from January 2013 to January
2014. Arak is the capital of Markazi Province with an
estimated population of over 500,000 and is situated in
a brucellosis-endemic area. The project was approved by
the Arak University of Medical Sciences ethics committee.
Informed consent was obtained from all subjects before
participation.
Patients were selected from among individuals
attending a private clinic in Arak. A clinical diagnosis of
brucellosis was made on the basis of the symptoms (such

as fever, night sweating, malaise, weakness, anorexia,
and weight loss), compatible clinical findings (such as
splenomegaly, arthralgia, lymphadenopathy, and myalgia),
and standard tube agglutination (STA = Wright) test
dilution of ≥1:160 in the presence of 2-mercaptoethanol
(2ME) agglutination, ≥1:40. The control group was
selected from among healthy individuals residing in the
same geographical area.
Serum samples were collected from brucellosis patients
before receiving any treatment and from controls. All
samples were tested for IL-17 and TGF-β levels by enzymelinked immunosorbent assay (ELISA). The commercial
enzyme immunoassay kits used were from Affymetrix
eBioscience, Vienna, Austria. All assay protocols, cutoffs,
and result interpretations were carried out according to
the manufacturer’s instructions.
All patients then received a regimen of doxycycline
(100 mg twice daily) plus rifampicin (600 mg daily) for
6–8 weeks. After treatment, serum samples were collected
again from patients and IL-17 and TGF-β levels were
tested with the same ELISA kits.
2.1. Statistical analysis
Data were entered into SPSS 16.0 (SPSS Inc., Chicago,
IL, USA). For data analysis, the Mann–Whitney U test
and Wilcoxon signed-rank test were used. P < 0.05 was
considered statistically significant. Data are presented as
the mean ± standard deviation or absolute number with
percentage, as indicated.
3. Results
TGF-β levels were tested in 33 acute brucellosis patients
and 19 age-matched controls. The mean age of patients
was 23.2 ± 15.2 years; 54.5% of them were male and 45.5%
were female. IL-17 levels were analyzed in 40 patients
(with mean age of 23.9 ± 15.6) and 12 controls. Among
those patients, 57.5% were male and 42.5% were female.
IL-17 and TGF-β levels of the study group (before and
after the treatment) and the control group are shown in
Table 1.
TGF-β levels was significantly lower in acute brucellosis
cases compared to the control group (P<0.001). At the
end of treatment, the serum levels of this cytokine had
increased, but there was no significant difference between
the mean level of this cytokine before and after treatment
(Wilcoxon signed-rank test) (Table 2).
The IL-17 level was significantly higher in the acute
brucellosis group compared to controls (P < 0.01) and its
value decreased in patients at the end of treatment without
any significant difference (Table 2).
4. Discussion
In this study, we analyzed serum TGF-β and IL-17 levels
in a control group and acute brucellosis patients before
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Table 1. Serum levels of TGF-β and IL-17 in the healthy control group and acute brucellosis patients before and after
treatment.
Acute brucellosis group

Cytokines

Control group

Before treatment

After treatment

TGF-β (pg/mL)

84.48 ± 47.46

91.2 ± 63.2

120.11 ± 40.61

IL-17 (pg/mL)

80.2 ± 125.9

67.9 ± 131.6

25.03 ± 32

Values are presented as mean ± standard deviation. TGF-β: Transforming growth factor beta, IL-17: interleukin-17.

Table 2. Mean levels of TGF-β and IL-17 in brucellosis patients before and after treatment (Wilcoxon signed-rank test).
Cytokines

Mean before brucellosis treatment

Mean after brucellosis treatment

P-value

TGF-β

15.6

16.2

0.13

IL-17

21.8

18.1

0.52

TGF-β: Transforming growth factor beta, IL-17: interleukin-17.

and after treatment. TGF-β was significantly lower and
IL-17 was significantly higher in acute brucellosis cases
compared to the control group. After treatment, the
serum levels of TGF-β increased and IL-17 decreased in
brucellosis patients without any significant difference.
The main defense against intracellular organisms like
Brucella is cellular immunity. Elimination of Brucella is
mediated by enhanced macrophage activation by Th1
cell-mediated immunity. Cytokines released during this
stimulation and produced by various cells in response
to proinflammatory mediators and bacterial products
play a critical role in the pathogenesis of brucellosis
(1,2,11,14,15).
TGF-β is secreted by many cell types, including
macrophages, in response to damaged tissues. TGF-β is a
very powerful immunosuppressive cytokine that blocks the
activation of lymphocytes and phagocytes and modulates
T-cell function (17,25).
Rafiei et al. (26) found that a high-producing haplotype
of the TGF-β gene was more common in brucellosis
patients than controls. Budak et al. (27) showed that
the frequency of the intermediate producer haplotype
of TGF-β was significantly higher in brucellosis patients.
In contrast, Bravo et al. (17) reported that the frequency of
high and intermediate producer genotypes of TGF-β were
significantly lower in patients compared with controls. In
a study by Akbulut et al. (28), no significant differences
were found between patient and control groups regarding
TGF-β levels. We found that TGF-β was significantly lower
in brucellosis cases than controls and, after brucellosis
treatment, the serum levels of TGF-β were increased.
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These discrepancies in results may be explained by
epidemiological, ethnic, and geographic variations and
study conditions such as the number of the patients.
Th17 cells mediate host immunity against extracellular
bacteria and fungi. These cells differentiate after exposure
to IL-1, TGF-β, and IL-6 (29). The main secreted cytokines
from Th17 cells are IL-17, IL-21, and IL-22 and their main
effector cells are neutrophils, IgM/IgA B cells, and IL-17
CD4 T cells (19). IL-17 is a proinflammatory cytokine
that has important functions in infectious diseases,
autoimmune disorders, and malignancies (30,31). IL17 is an important link between the adaptive and innate
immune responses and it is required for the induction of
IFN-γ and IL-12 in macrophages and dendritic cells. It
seems that IL-17 can affect the activation of Th1 immunity,
which is necessary for controlling Brucella infection (10).
We found that the IL-17 level was significantly higher
in brucellosis cases than controls and, after brucellosis
treatment, the serum levels of IL-17 were decreased. We
could not find any study on IL-17 levels in brucellosis
patients so it was impossible to compare our results
to others studies, but there are a few surveys on the
importance of IL-17 in brucellosis immunopathogenesis,
as we showed in our investigation. Clapp et al. (32) showed
that a live brucellosis vaccine that is capable of stimulating
potent Th17 cell responses can contribute to the protection
against mucosal challenge with B. abortus. Rasouli et al.
(10) reported that the IL-17 rs4711998, rs8193038, and
rs3748067 AA genotypes and AAGAA haplotype could be
considered as susceptibility factors for brucellosis while the
IL-17 rs3819024GG and rs3819025AA genotypes might
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be resistance factors against the disease. These findings
suggest that IL-17 may have a main role in the protection
against Brucella infection.
In conclusion, our results indicated that TGF-β and
IL-17 are involved in the pathogenesis of brucellosis and
the levels of these cytokines can influence the outcome of
brucellosis infection. Due to the low number of patients

in our study, these results need to be confirmed in larger
patient cohorts and with subjects from different ethnic
groups.
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